Ferring-Leciva, A.S. is the Czech Republic affiliate and manufacturing operation of Ferring, a research-driven specialty biopharmaceutical group. The company is active in the development, manufacturing and commercialization of prescription pharmaceutical therapies, with strategic therapeutic focus areas centered on reproductive medicine and maternal health, as well as specialty segments within gastroenterology and urology. Operations include a manufacturing base in the Czech Republic supporting Ferring supply capabilities and the lifecycle management of specialty products, alongside local market activities related to medical affairs, stakeholder engagement and distribution of Ferring therapies. The companys geographic scope combines domestic presence in the Czech Republic with integration into Ferrings global network of R&D, manufacturing and commercial operations serving international markets. Key assets include the Ferring scientific and specialty-pharma platform, established expertise in fertility and maternal health therapies, and the Jesenice-based production footprint supporting quality-controlled manufacturing under global standards. Strategic positioning is anchored in innovation-led specialty care, patient impact in family building and chronic specialty indications, and continued investment in research, clinical development, regulatory compliance and high-quality production to support both local and global demand across targeted therapeutic domains.
Headquarters
K Rybniku 475
Jesenice; Stredocesky;
Postal Code: 25242
Contact Details: Purchase the Ferring-Leciva, A.S. report to view the information.
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service